The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | The promise of CPX-351 in secondary AML
Fabio Guolo, MD, University of Genoa, Genoa, Italy, discusses his view that CPX-351 is the best treatment currently available for secondary acute myeloid leukemia (AML). This drug has high response rates and is well-tolerated, allowing these patients to progress to allogeneic stem cell transplantation (alloSCT). Dr Guolo highlights that patients should be fit for intensive chemotherapy. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
